The Effects of Consumption of Pomegranate Juice on Carotid Intima-Media Thickness

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00728299
Recruitment Status : Completed
First Posted : August 5, 2008
Last Update Posted : August 5, 2008
Roll International Corporation
Information provided by:
Radiant Research

Brief Summary:
Increases in carotid artery intima-media thickness (IMT) are correlated with increased risk of stroke and myocardial infarction. The purpose of this study is to assess if pomegranate juice will retard the carotid (IMT) progression rate in men and women who have one or more existing cardiovascular risk factors (current cigarette smoking, hypertension, low HDL-cholesterol, and/or high LDL-cholesterol) upon entrance into the study.

Condition or disease Intervention/treatment Phase
Coronary Artery Disease Drug: PomWonderful Juice Drug: Placebo juice Not Applicable

Detailed Description:

Previous studies in atherosclerotic mice have shown that pomegranate supplementation reduced their macrophage oxidative stress and attenuated the development of their atherosclerosis. Further research in hypertensive humans demonstrated that pomegranate juice had an angiotensin converting enzyme (ACE)-inhibitory effect and significantly decreased systolic blood pressure.

This study will use a randomized, double-blind, placebo-controlled design with eight clinic visits (one screening visit [week -4 to -1], one baseline visit [week 0], and six treatment visits [weeks 13, 26, 38, 52, 65, and 78]).

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 384 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: The Effects of Consumption of Pomegranate Juice on Carotid Intima-Media Thickness
Study Start Date : September 2003
Actual Primary Completion Date : September 2005
Actual Study Completion Date : September 2005

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1 Drug: PomWonderful Juice
8 oz per day each day for 78 weeks
Placebo Comparator: 2 Drug: Placebo juice
8 oz per day for 78 weeks

Primary Outcome Measures :
  1. Difference in posterior wall common carotid intima-media thickness (IMT) progression rate in mm/yr between PomWonderful juice and placebo, utilizing non-contrast images [ Time Frame: 78-90 weeks ]

Secondary Outcome Measures :
  1. Difference between placebo and PomWonderful juice in internal carotid artery IMT progression rate in mm/yr [ Time Frame: 78-90 weeks ]
  2. Difference between placebo and PomWonderful juice in the carotid bifurcation IMT progression rate in mm/yr [ Time Frame: 78-90 weeks ]
  3. Difference between placebo and PomWonderful juice in the anterior wall common carotid IMT progression rate in mm/yr, without contrast agent [ Time Frame: 78-90 weeks ]
  4. Difference between placebo and PomWonderful juice in the anterior wall common carotid IMT progression rate in mm/yr, with contrast agent [ Time Frame: 78-90 weeks ]
  5. Difference between placebo and PomWonderful juice in the posterior wall common carotid IMT progression rate in mm/yr, with contrast agent [ Time Frame: 78-90 weeks ]
  6. Difference between placebo and PomWonderful juice in the composite IMT measure, which combines the measurements of the common and internal carotid and the carotid bifurcation in mm/yr [ Time Frame: 78-90 weeks ]
  7. Change from baseline to 13 weeks in hs-CRP concentration [ Time Frame: 13 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   45 Years to 74 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Males between the ages of 45 and 74 and females between the ages of 55 and 74 years.
  • Subject has ≥ 1 of the following risk factors at Visit 1 (week -4 to -1):

    • current cigarette smoking (defined as any cigarette smoking within the past month)
    • hypertension (blood pressure ≥ 140/90 mm Hg or using an antihypertensive medication)
    • low HDL cholesterol (< 40 mg/dL)
    • high LDL cholesterol (≥ 130 mg/dL and < 190 mg/dL), on statin therapy or not
  • Posterior wall common carotid IMT > 0.7 mm and < 2.0 mm at Visit 2 (week 0) with an adequate image on at least one side.
  • Subject understands the study procedures and signs an informed consent form.
  • Normally active and judged to be in good health on the basis of medical history, physical examination, and routine laboratory tests.

Exclusion Criteria:

  • Use of any pharmacologic lipid-altering medications, besides statins (e.g., fibrate derivatives, bile acid binding resins, and niacin or its analogues at doses > 400 mg/d) six weeks prior to Visit 1
  • Body mass index > 40 kg/m2.
  • Unstable use (< 2 months prior to Visit 1) of any supplement known to alter lipid metabolism, including but not limited to: dietary fiber supplements (including > 2 teaspoons Metamucil® or psyllium-containing supplement per day), omega-3 fatty acid supplements, sterol/stanol products, red rice yeast supplements, garlic supplements, soy isoflavone supplements or others at the discretion of the Investigator).
  • History of pomegranate consumption (either eating pomegranates or drinking pomegranate juice) within the past 6 months.
  • Clinical evidence or history of coronary heart disease (CHD) or CHD equivalents including:

    • diabetes mellitus,
    • angina,
    • myocardial infarction,
    • transient ischemic attack,
    • symptomatic carotid artery disease,
    • cerebrovascular accident,
    • coronary artery bypass grafting,
    • percutaneous transluminal coronary angioplasty,
    • peripheral arterial disease,
    • abdominal aortic aneurysm,
    • ankle brachial index < 0.90,
    • and/or a Framingham Risk Score ≥ 16 points for men and ≥ 23 points for women (10-year CHD risk > 20%)
  • Active cancer, other than non-melanoma skin cancer, within the previous two years.
  • Prior diagnosis of human immunodeficiency virus (HIV) or hepatitis B or hepatitis C.
  • Uncontrolled hypertension (average systolic blood pressure ≥ 160 mm Hg and/or average diastolic blood pressure ≥ 100 mm Hg).
  • Untreated or unstable hypothyroidism (receiving stable dose therapy for < 4.0 months).
  • Concomitant use of beta-adrenergic blockers or immunosuppressants
  • Concomitant use of estrogen or progestin therapy.
  • Allergy to pomegranates or pomegranate juice.
  • Known allergy to blood products.
  • Non-English speaking.
  • Active liver disease or hepatic dysfunction as defined by elevations of ≥ 2.0 x ULN at Visit 1 in any of the following liver function tests: ALT, AST or bilirubin.
  • Serum creatinine > 2.0 mg/dL recorded during screening period.
  • Recent history of (within past 12 months) or strong potential for alcohol or substance abuse. Alcohol abuse will be defined as >14 drinks per week (1 drink = 12 oz beer, 4 oz wine, or 1 ½ oz distilled spirits).
  • Participation in another clinical study within 30 days prior to screening visit 1 (week -4 to -1).
  • Has a condition the Investigator believes would interfere with evaluation of the subject, or may put subject at undue risk.
  • Posterior wall common carotid IMT ≥ 2.0 mm on either side at Visit 2 (week 0).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00728299

Sponsors and Collaborators
Radiant Research
Roll International Corporation
Principal Investigator: Michael H Davidson, MD FACC

Responsible Party: Michael H. Davidson, MD, Executive Medical Director,, Radiant Research Identifier: NCT00728299     History of Changes
Other Study ID Numbers: Radiant Development #202528
First Posted: August 5, 2008    Key Record Dates
Last Update Posted: August 5, 2008
Last Verified: August 2008

Keywords provided by Radiant Research:
Coronary artery disease, carotid intima-media thickness

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases